BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31242976)

  • 21. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
    Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
    Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
    J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review.
    Winquist E; Agbassi C; Meyers BM; Yoo J; Chan KKW;
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):29. PubMed ID: 28376866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216).
    Adelstein DJ; Moon J; Hanna E; Giri PG; Mills GM; Wolf GT; Urba SG
    Head Neck; 2010 Feb; 32(2):221-8. PubMed ID: 19557750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
    Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
    J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).
    Shapiro LQ; Sherman EJ; Riaz N; Setton J; Koutcher L; Zhang Z; Shi W; Fury MG; Wolden SL; Pfister DG; Morris L; Lee N
    Oral Oncol; 2014 Oct; 50(10):947-55. PubMed ID: 25132089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx.
    Fallai C; Bolner A; Signor M; Gava A; Franchin G; Ponticelli P; Taino R; Rossi F; Ardizzoia A; Oggionni M; Crispino S; Olmi P
    Tumori; 2006; 92(1):41-54. PubMed ID: 16683383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
    Nguyen-Tan PF; Zhang Q; Ang KK; Weber RS; Rosenthal DI; Soulieres D; Kim H; Silverman C; Raben A; Galloway TJ; Fortin A; Gore E; Westra WH; Chung CH; Jordan RC; Gillison ML; List M; Le QT
    J Clin Oncol; 2014 Dec; 32(34):3858-66. PubMed ID: 25366680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Concurrent simultaneous integrated boost radiotherapy and cetuximab in head and neck squamous cell cancer patients: is it feasible in daily clinical practice?].
    Chillari F; Parisi S; Ferrantelli G; Carrubba C; Santacaterina A; Critelli P; Sciacca M; Venuti V; Lillo S; Cacciola A; Iatì G; Pontoriero A; Platania A; Delia P; Tombolini V; De Felice F; Musio D; Spatola C; Brogna A; Pergolizzi S
    Recenti Prog Med; 2024 May; 115(5):1e-6e. PubMed ID: 38708539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial.
    Sharma A; Mohanti BK; Thakar A; Bahadur S; Bhasker S
    Ann Oncol; 2010 Nov; 21(11):2272-2277. PubMed ID: 20427350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer.
    Maguire PD; Papagikos M; Hamann S; Neal C; Meyerson M; Hayes N; Ungaro P; Kotz K; Couch M; Pollock H; Tepper J
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1081-8. PubMed ID: 20378262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
    Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
    Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors.
    Krstevska V; Stojkovski I; Zafirova-Ivanovska B
    Radiat Oncol; 2012 May; 7():78. PubMed ID: 22640662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
    Pinnarò P; Cercato MC; Giannarelli D; Carlini P; Del Vecchio MR; Impiombato FA; Marzetti F; Milella M; Cognetti F
    Ann Oncol; 1994 Jul; 5(6):513-9. PubMed ID: 7918123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer.
    Zhao Q; Wang Z; Huang W; Wang Q; Yu S; Zhou T; Han D; Wu Z; Gong H; Sun H; Zhang J; Wei Y; Li H; Zhang Z; Lin H; Li B
    Oncotarget; 2016 Feb; 7(7):8422-31. PubMed ID: 26761213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
    Yao M; Woods C; Lavertu P; Fu P; Gibson M; Rezaee R; Zender C; Wasman J; Sharma N; Machtay M; Savvides P
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1770-6. PubMed ID: 26918562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
    Hu Q; Li F; Yang K
    PeerJ; 2024; 12():e17391. PubMed ID: 38784388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoradiotherapy with high-dose cisplatin compared with weekly cisplatin for locally advanced head and neck squamous cell carcinoma.
    Hughes RT; Porosnicu M; Levine BJ; Lycan TW; Shenker RF; Frizzell BA; Greven KM
    J Med Imaging Radiat Oncol; 2021 Oct; 65(6):796-805. PubMed ID: 34309212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas. Preliminary results of a phase II, single-institutional trial.
    Arias de la Vega F; Domínguez Domínguez MA; Manterola Burgaleta A; Vera García R; Echeverría Zabalza ME; Oria Mundin E; Martínez López E; Romero Rojano P; Villafranca Iture E
    Clin Transl Oncol; 2005 Mar; 7(2):60-5. PubMed ID: 15899210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.